Can you give a concise presentation on allergic bronchopulmonary aspergillosis (ABPA), including its epidemiology, pathophysiology, clinical features, diagnostic criteria, and treatment recommendations?

Allergic Bronchopulmonary Aspergillosis (ABPA): Clinical Presentation

Overview and Definition

ABPA is a complex hypersensitivity reaction to Aspergillus fumigatus colonizing the airways, primarily occurring in patients with asthma or cystic fibrosis, and requires early recognition to prevent irreversible bronchiectasis. 1 This condition represents a distinct asthma endotype and treatable trait that responds exceptionally well to specific therapy when identified promptly 1.

Epidemiology

• Global burden: Approximately 5 million cases worldwide, with India accounting for 1.4 million cases 2
• Prevalence in asthma: Up to 13% in specialized asthma clinics 2
• Predisposing conditions: Most commonly asthma and cystic fibrosis, but also occurs in COPD, bronchiectasis, and rarely without underlying lung disease 1
• Recent data: In Chinese adults with asthma-COPD overlap, ABPA occurrence was 12.8% in nonsmokers and 6.6% in smokers 3

Pathophysiology

ABPA results from a complex interplay between fungal colonization and host immune dysregulation 4:

• Type 2 inflammatory response: Hypersensitivity reaction mounted against A. fumigatus antigens in the airways
• Fungal growth: Unlike simple sensitization, the fungus actively grows within the airways, distinguishing ABPA from other allergic conditions 1
• Tissue damage: Persistent inflammation leads to mucus plugging, bronchiectasis, and potential progression to pulmonary fibrosis
• Immune markers: Elevated IgE (both total and A. fumigatus-specific), IgG antibodies, and peripheral eosinophilia characterize the immune response

Clinical Features

Cardinal Symptoms

• Uncontrolled asthma: Treatment-resistant asthma with persistent wheezing and dyspnea 4, 2
• Chronic productive cough: Often with expectoration of brownish or black mucus plugs (pathognomonic when present) 4
• Recurrent pulmonary infiltrates: Fleeting opacities on imaging that come and go 4, 2

Key Clinical Presentations

• Expectoration of mucus plugs
• Finger-in-glove opacities on imaging
• Lung collapse from mucus impaction
• Progressive dyspnea and chest pain 5

Uncommon Presentations

Pleural involvement is exceedingly rare but documented, including pyopneumothorax, effusion, hydropneumothorax, and empyema 5. These complications arise from immune-mediated pleural inflammation or secondary infections.

Diagnostic Criteria (2024 ISHAM-AWG Revised Guidelines)

Essential Components (BOTH Required)

1. A. fumigatus-specific IgE ≥0.35 kUA·L⁻¹ 1
2. Serum total IgE ≥500 IU·mL⁻¹ 1

Additional Components (ANY TWO Required)

1. Positive IgG against A. fumigatus (cut-offs: ≥27, ≥60, or ≥40 mgA·L⁻¹ for India, Japan, UK respectively) 1
2. Blood eosinophil count ≥500 cells·μL⁻¹ (historical values acceptable) 1
3. Characteristic imaging findings:
   • Thin-section chest CT: bronchiectasis, mucus plugging, high-attenuation mucus (HAM)
   • Chest radiograph: fleeting opacities 1

Critical Diagnostic Considerations

• High-attenuation mucus is pathognomonic and confirms ABPA diagnosis even if other criteria are incomplete 1
• Total IgE <500 IU·mL⁻¹ may be acceptable if all other criteria are fulfilled (can occur with prior glucocorticoid treatment, elderly patients, or constitutively low baseline IgE) 1
• Skin testing acceptable when Aspergillus-IgE unavailable 1
• Elevated IgE against recombinant antigens (rAsp f1, f2, f4) supports diagnosis 1

Diagnostic Algorithm 1

Step 1: Screen for A. fumigatus-specific IgE in:

• All newly diagnosed asthmatic adults at tertiary care
• Difficult-to-treat asthmatic children 1

Step 2: If A. fumigatus-IgE ≥0.35 kUA·L⁻¹ → measure serum total IgE

Step 3: If total IgE ≥500 IU·mL⁻¹ → perform:

• A. fumigatus-specific IgG
• Peripheral blood eosinophil count
• Thin-section chest CT
• Pulmonary function tests

Step 4: Classify based on imaging findings:

• ABPA-S (serological): No bronchiectasis
• ABPA-B: Bronchiectasis present
• ABPA-MP: Mucus plugging
• ABPA-HAM: High-attenuation mucus
• ABPA-CPF: Chronic pleuropulmonary fibrosis

Investigations NOT Recommended

• Serum galactomannan: Not recommended for diagnosis 1
• Bronchoscopy: Not routinely recommended 1
• Sputum fungal culture: Suggested but not essential for ABPA (mandatory for ABPM diagnosis) 1

Imaging Recommendations

• Baseline: Thin-section chest CT to identify bronchiectasis, mucus plugging, HAM 1
• Follow-up: Chest radiograph for treatment response assessment 1

Differential Diagnosis and Pitfalls

Common misdiagnoses include:

• Tuberculosis: Particularly in endemic regions due to overlapping radiological features 5
• Chronic pulmonary aspergillosis: Can have elevated A. fumigatus antibodies but different clinical context
• Aspergillus bronchitis: Seen in bronchiectasis/CF without meeting ABPA criteria
• Eosinophilic pneumonia: Different immunological profile
• Severe asthma with Aspergillus sensitization: Sensitization alone without ABPA criteria

Critical distinction: A. fumigatus-specific IgE and IgG can be elevated in COPD, tuberculosis, and bronchiectasis without ABPA—diagnosis requires meeting full criteria 1.

Treatment Recommendations (2024 ISHAM-AWG Guidelines)

Asymptomatic ABPA

Do not routinely treat asymptomatic patients 1

Acute ABPA (Newly Diagnosed or Exacerbation)

Recommend oral prednisolone OR itraconazole monotherapy 1

Recurrent ABPA Exacerbations

Recommend prednisolone AND itraconazole combination therapy 1

Treatment Monitoring

• First exacerbation: 90.91% occur within 2 years of diagnosis 6
• Follow-up: Monitor serum IgE changes (ΔIgE) during this critical period 6
• Compliance challenge: Only 31.91% of patients adhere to standardized hormone therapy after 4 weeks 6

Refractory Disease

Biological agents may be used for severe disease or glucocorticoid dependence 1:

• Omalizumab most commonly used first-line
• Switching to anti-IL-5/IL-5 receptor agents (mepolizumab, benralizumab) for inadequate response
• Dupilumab as subsequent option 7

Allergic Bronchopulmonary Mycosis (ABPM)

Consider ABPM when: ABPA-like presentation but A. fumigatus-IgE <0.35 kUA·L⁻¹ 1

Additional requirement: Repeated growth of causative fungus from ≥2 sputum specimens or 1 bronchoalveolar lavage 1

Diagnostic support: Absence of elevated IgE against rAsp f1, f2, f4 strongly supports ABPM over ABPA 1

Prognostic Considerations

Early identification and treatment are crucial to prevent progression to irreversible bronchiectasis and pulmonary fibrosis 1. Complications from delayed treatment include:

• Bronchiectasis with chronic sputum production
• Pulmonary fibrosis
• Severe persistent asthma with progressive lung function loss 8, 9

Risk factors for ABPA in asthma-COPD overlap: Coexisting atopic conditions, rural residence, biomass use, and longer asthma duration 3